Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Impact · against what's priced in

Moderna eliminates long-term royalty uncertainty for its vaccine pipeline in exchange for a $950 million immediate cash hit and a $1.3 billion contingent liability. Arbutus receives a significant immediate cash infusion and a potential multi-billion dollar upside depending on the Federal Circuit's ruling.

ABUS+0.60: No priced-in read yet
In context: The company secures a $950 million lump sum payment and creates a path to an additional $1.3 billion depending on the outcome of the Section 1498 appeal.
Read from the article alone

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

pharmaceuticals
biotech
ABUS
MRNA
intellectual property
legal dispute
mrna
patent litigation
settlement
vaccines

Search tags

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

What matters in this story

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

What matters in this story

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

How each ticker is affected

Connected tickers

Track these names every morning.

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Kaplan Fox Announces a Securities Class Action Filed Against Ardelyx, Inc. (ARDX) - Lead Plaintiff Deadline is November 16, 2026

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

What matters in this story

Next reads from the same story arc

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

What matters in this story

Next reads from the same story arc

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

How each ticker is affected

Connected tickers

Track these names every morning.

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Kaplan Fox Announces a Securities Class Action Filed Against Ardelyx, Inc. (ARDX) - Lead Plaintiff Deadline is November 16, 2026

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures